MedTrace Logo

Induction of Migraine Aura With Cilostazol

NCT02253004 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2015-08-21

No results posted yet for this study

Summary

In a double blind placebo-controlled cross-over study the effect of cilostazol on aura induction and endothelial response is tested in patient with migraine with aura.

Conditions

Interventions

DRUG

Cilostazol

Single oral administration of active or placebo one week apart

DRUG

Placebo

Sponsors & Collaborators

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • Christina Kruuse, MD PhD DMSc · Consultant Neurologist, Dept Neurology

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02253004 on ClinicalTrials.gov